Results 201 to 210 of about 45,696 (262)

Ceftazidime/avibactam serum concentration in patients on ECMO

Journal of Antimicrobial Chemotherapy
Abstract Objectives The use of extracorporeal membrane oxygenation (ECMO) may alter blood levels of several drugs, including antibiotics, leading to under dosing of these drugs and thus to potential treatment failure.
Anaïs Curtiaud, Matthieu Petit, Juliette Chommeloux, Marc Pineton de Chambrun, Guillaume Hekimian, Matthieu Schmidt, Alain Combes, Charles-Edouard Luyt   +7 more
openaire   +3 more sources

Safety evaluation of ceftazidime/avibactam based on FAERS database

Infection
To explore adverse event (AE) signals of Ceftazidime/avibactam (CZA) based on the FDA Adverse Event Reporting System (FAERS) database.AE reports primarily associated with CZA were retrieved from the FAERS database from the second quarter of 2015 to the second quarter of 2023.
Xiuhong, Zhang, Ying, Jiang, Yating, Guo, Wenbo, Zhou, Weizhen, Qiao, Haohao, Zhu, Zhigang, Qi   +6 more
openaire   +3 more sources

The primary pharmacology of ceftazidime/avibactam: resistancein vitro

Journal of Antimicrobial Chemotherapy, 2023
AbstractThis article reviews resistance to ceftazidime/avibactam as an aspect of its primary pharmacology, linked thematically with recent reviews of the basic in vitro and in vivo translational biology of the combination (J Antimicrob Chemother 2022; 77: 2321–40 and 2341–52).
Wright W Nichols, Sushmita D Lahiri, Patricia A Bradford, Gregory G Stone   +3 more
openaire   +2 more sources

Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae

Antimicrobial Agents and Chemotherapy, 2017
We determined imipenem, imipenem-relebactam, ceftazidime, and ceftazidime-avibactam MICs against 100 CRE isolates that underwent whole-genome sequencing.
Ghady Haidar, Cornelius J Clancy, Liang Chen   +2 more
exaly   +2 more sources

Ceftazidime/avibactam‐induced severe neutropenia: A case report

British Journal of Clinical Pharmacology, 2023
AbstractCeftazidime/avibactam is an important option for the treatment of infections caused by multidrug‐resistant gram‐negative bacteria. Haematological abnormalities are rare adverse events. We describe a case of a 63‐year‐old male who developed severe neutropenia following exposure to ceftazidime/avibactam in the intensive care unit for the ...
Weifang Wu, Yangxiao Lai, Yiheng Lin, Tong Li   +3 more
openaire   +2 more sources

Global trends of ceftazidime–avibactam resistance in gram-negative bacteria: systematic review and meta-analysis

Antimicrobial Resistance and Infection Control
The emergence of antimicrobial resistance in Gram-negative bacteria (GNB) is a major global concern. Ceftazidime–avibactam (CAZ–AVI) has been identified as a potential treatment option for complicated infections.
Yang Wang, Mohammad Sholeh, Lu Yang, Matin Zafar Shakourzadeh, M. Beig, K. Azizian   +5 more
semanticscholar   +1 more source

A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing Klebsiella pneumoniae infections and on

Antimicrobial Agents and Chemotherapy
To assess the impact of a multidisciplinary approach aimed at attaining aggressive joint pharmacokinetic/pharmacodynamic (PK/PD) target with ceftazidime/avibactam on treatment outcome of KPC-Klebsiella pneumoniae (Kp) infections and prevention of ...
Milo Gatti, M. Rinaldi, Piergiogio Cojutti, Cecilia Bonazzetti, A. Siniscalchi, T. Tonetti, S. Ambretti, S. Tedeschi, M. Giannella, P. Viale, F. Pea   +10 more
semanticscholar   +1 more source